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In the nineteenth century, researchers discovered that some proteins had the ability to 
agglutinate red blood cells (Goldstein, 1980). These proteins were found mainly in the seeds of 
leguminous plants and were named phytohemagglutinins or hemagglutinins. Particular 
hemagglutinins were able to agglutinate red blood cells (RBCs) of a specific blood type. Now a 
days, these proteins are more widely known as Lectins. Lectins are proteinaceous 
macromolecules of nonimmune origin, capable of interacting with carbohydrates to form 
complexes (Goldstein, 1980). Lectins sources derive mainly from leguminous plants, animals, 
fruiting bodies of fungi, and bacteria. This research focuses on identifying the lectin activity and 
characteristics of certain synthetic compounds. Lectin activity was assessed by 
observing   agglutination reactions of synthetic compounds and human red blood cells of a 
known human blood group and type in the ABO system. Lectins continue to be the focus of 
research due to their potential diverse applications specifically for blood grouping, mitogenic 



















    Introduction 
Lectins are proteinaceous macromolecules of nonimmune origin, capable of interacting 
with carbohydrates to form complexes (Goldstein, 1980). Lectins are derived from a variety  of 
sources. They are widely seen in seeds of leguminous plants, animals, fruiting bodies of fungi, 
and bacteria. 
In the 19th century, researchers discovered the ability of some proteins to agglutinate red 
blood cells (Goldstein, 1980). These proteins, mainly found in the seeds of leguminous plants, 
were named phytohemagglutinins or hemagglutinins (Gorakshakar, & Ghosh, 2016). Later, 
particular hemagglutinins were found to agglutinate red blood cells (RBC’s) of a particular 
human blood type in the ABO blood group system. As a result, in 1954, Boyd and Shapleigh 
named these hemagglutinins “lectins” from the Latin word legere, meaning “to choose” or “to 
select” (Goldstein, 1980). 
In 1888, Peter Hermann Stillmark isolated toxic extracts from seeds of the castor tree, 
Ricinus communis, and found that these hemagglutinating proteins agglutinated human 
erythrocytes and named them “ricin” (Lis & Sharon, 2004). Similarly, in 1891, as the 19th 
century sparked collaborative efforts for early research in protein agglutinating activity, H. 
Hellin isolated abrin, toxic protein obtained from the seeds of the jequirity bean, Abrus 
precatorius, which is similar in structure and properties to ricin (Dickers, Bradberry, Rice, 
Griffiths, & Vale, 2003). However, it was not until 1919, that Sumner isolated extracts from jack 
bean seeds (Canavalia ensiformis), purified it for the first time, and named it concanavalin A 
(Goldstein, 1980). 
Further research into the agglutinating properties of lectins quickly ensued with a 
particular focus on research aimed at identifying new lectin sources. In 1940, William Boyd and 
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Karl Renkonen discovered that extracts of lima bean, Phaseolus limensis, agglutinated type A 
human red cells but not type B or type O (Lis & Sharon, 2004). In 1959, G. W. G. Bird reported 
that precipitins from Dolichos biflorus seeds reacted with part of the A‐substance of human red 
blood cells; specifically, an A-substance component found in individuals with sub‐groups A1 
(Bird, 1959; Etzler & Kabat, 1970). Extracts from the asparagus pea, agglutinated type O human 
red cells but no other red cell types (Sharon & Lis, 2004). 
Lectins continue to be the focus of research due to their potential and diverse applications 
specifically for blood grouping, mitogenic activity, challenges related to polyagglutination, and 
stem cell transplantation (Hammid, Masood, & Rafiq, 2013). There has been great effort in 
characterizing legume-derived lectins (Hamid, Masood, Wani, & Rafiq, 2013; Lagarda-Diaz, 
Guzman-Partida, Vazquez-Moreno, 2017) and their positive and negative health effects. The 
study of lectins remains a prolific field with novel lectins becoming the focus of recent studies (e 
Lacerda et al., 2017; Torres et al, 2019).  
Specific applications of lectins hinge on meticulous characterization of their properties 
and the identification of carbohydrate-specific binding sites. This research will focus on 
determining lectin properties of synthetically produced Glucuronate, Alginate, and related 
Boronates and aims to categorize the compounds according to their lectin-characteristic 
structures followed by their selective interaction with human red cells. These compounds have 
been previously screened for Lectin properties; however, specificity was within the scope of that 










The agglutination of human red blood cells will be used as an indication of lectin activity. 
Agglutination is a standard serological method in the clinical laboratory to detect antibody-
antigen interactions through visible clumping or agglutination.  
In immunohematology, commonly known as blood banking, determinations of antigen 
and antibodies are the key to identifying blood groups, unexpected antibodies, and making sure 
blood compatibility is achieved. Antibodies are glycoproteins capable of recognizing a specific 
antigen. Antibodies concerning the blood bank are present in the serum and plasma. In contrast, 
antigens relevant to immunohematology are found on the cell membrane of red blood cells. 
Hemagglutination occurs when an antigen binds with a corresponding antibody. In the blood 
bank, hemagglutination is graded on basis of 4+, 3+, 2+, 1+, Negative. A 4+ is a visible red cell 
solid agglutinate with a clear background. A 3+ are several large red agglutinates with a clear 
background. A 2+ are may medium-sized agglutinins with a clear background. A 1+ are many 
medium and small sized agglutinates with a reddish turbish background. Negative is the absence 




Figure 1. This figure shows the agglutination reactions from 4+ to a negative (0). A positive reaction raises awareness that there 




While previous research indicates that red cell agglutination has been observed with 
certain synthetically derived compounds, studies on specificity were not conducted (Koshar, 
2018). Therefore, the focus of this study was to first confirm previous findings reported on initial 
testing as reported by Koshar (2018), followed by specificity testing.  
Testing Protocol 
Type A, B, and O human red blood cells, from voluntarily donated units were used and 
five compounds were donated by the Andrews Chemistry department and Dr. Murray. Donated 
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blood is collected in bags containing acid citrate dextrose (ACD)-A, which contains 3% citrate to 
prevent coagulation and maximize cell life. Red cells for testing are prepared by washing the 
cells 3-4 times with 0.85% NaCl (isotonic saline). The washed red cells were then used to 
prepare a 2-5% red cell suspension in saline. The 2-5% red cell suspension was prepared as 
follows: To a labeled tube, I added 1 mL of whole blood. After I added the blood, I washed cells 
in saline for 5 minutes four times, removed last aspiration, and kept the pellet. Next, I added .3 
mL of washed cells to another tube with 9.7 mL of saline. After adding washed cells with saline, 
I capped the tube with parafilm and shook it to obtain 2-3% red cell suspension or centrifuge for 
15 seconds a total of 3-4 times. Finally, I added enough saline to achieve an adequate 2-5% red 
cell suspension.  
A stock solution for each compound was prepared by adding 0.02 grams of each of the 
synthetically produced compounds to 1 mL of DMSO. The solution was mixed until dissolved. 
Testing for hemagglutination was performed as follows: 
1. Label 6 test tubes with respective compounds. 
2. Add one drop of compound (ID) stock solution to each test tube. 
3. Add 1 drop of 2-5% human red blood cell suspensions (refer to procedure for 
preparing a 2-5% red cell suspension) 
4. Centrifuge for 15 seconds. 
5. Examine tubes both macroscopically and microscopically for the presence of 
agglutination. 
The tubes were examined macroscopically through grading of the tube using the standard 
grading method procedure on a scale of 4+-0. Additionally, I examined the tubes microscopically 
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through looking for clumping of cells with the aid of a microscope. Agglutination was observed 
through agglutination of cells, or clumping of cells.  
Preparation of Controls 
Controls for each stock solution were also prepared. However, initially there were some 
challenges in obtaining a suitable control. This had to do with DMSO, the solvent, causing the 
red cells to agglutinate. This reaction was unexpected because in previous studies (Koshar, 2018) 
this was not mentioned. To remediate this problem, a negative control was obtained by adding a 
1:2 dilution of saline with DMSO as the control. It was necessary to have the DMSO and red cell 
suspension show no agglutination. This would allow the researcher to attribute any degree of 
agglutination to the compound and not the solvent. A negative control was achieved by diluting 
the DMSO with 0.85% NaCl. 
A negative control was obtained with added compound and .5 ml of saline and .5 ml of 
DMSO. Additionally, a negative was also obtained with added compound and .5 ml of DMSO 
and .25 ml of saline. Thus, a negative control of .5 ml of DMSO and .25 ml of saline was used. 
Additionally, a prewarming technique was used in this experiment. First, the stock solution was 
heated at 37 degrees for 10 minutes as well as heating up each of the blood types. After heating 
up the stock solution and blood types, one drop of type A, B and O positive cells were placed in 
single tubes with stock solutions. At the end of the ten minutes, the tubes were centrifuged and 





Five synthetically produced compounds were used in this experiment: three glucuronic 
acid boronates and two acetylneuraminic acid boronates. The five compounds tested were 4-
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bromomethyl phenyl boronic acid and glucuronic acid, 2-bromomethyl phenyl boronic acid and 
glucuronic acid, 3-bromomethyl phenyl boronic acid and glucuronic acid, 2-bromomethyl phenyl 
boronic acid and acetylneuraminic acid, and 3-bromomethyl phenyl boronic acid and 
acetylneuraminic acid. Solubility proved to be a problem; therefore, only two compounds were 
ultimately tested for lectin properties through agglutination. Solubility was a problem because 
only 2 compounds out of five were tested. Three compounds didn’t dissolve originally with the 
DMSO and thus were not used in the experiment.  
 The two semi-soluble compounds were 4-bromomethyl phenyl boronic acid and 
glucuronic acid (compound 1) and 2-bromomethyl phenyl boronic acid and acetylneuraminic 
acid (compound 6). These two compounds were tested with type A Rh positive, type B Rh 
positive, and type O Rh positive human red blood cells to determine their hemagglutinin 
characteristics. Neither compound showed macroscopic agglutination. Compound 1 did not show 
microscopic agglutination for any of the red cell types. In contrast, compound 6 did show some 
microscopic reactions. When tested with A cells (Figure 2), no microscopic agglutination was 
observed. The results were similar with O cells (figure 4). However, when tested with B positive 






Compound Name Compound 
number 
Used in the 
experiment 
4-bromomethyl phenyl boronic acid and glucuronic 
acid 
Compound 1 Yes 
3-bromomethyl phenyl boronic acid and glucuronic 
acid 
Compound 2 No 
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2-bromomethyl phenyl boronic acid and glucuronic 
acid 
Compound 3 No 
3-bromomethyl phenyl boronic acid and 
acetylneuraminic acid 
Compound 4 No 
2-bromomethyl phenyl boronic acid and 
acetylneuraminic acid 
Compound 6 Yes 
 
Figure 2. The above synthetic compounds describe the compounds that were used and not used in this research. In total, five 
compounds were donated by the chemistry department, but only two were used in the research because only two compounds 
were soluble enough to be tested. 
 
Controls consisted of 0.5 mL of DMSO and 0.5 mL of normal saline along with each of 
three red blood cell types. All controls were negative for agglutination suggesting that any 
agglutination observed in the solution with the compound would be attributed to the compound.  







Figure 3. This figure shows 
compound 6 with A positive cells. 
There is no visible agglutination. 
Figure 4. This figure shows 
compound 6 with B positive cells. 
There is slight agglutination in 
comparison with other cells. 
Figure 5. This figure shows 
compound 6 with O positive cells. 




       Discussion 
 
        Five compounds were used in this experiment. However, solubility was a problem and only 
two compounds were successfully dissolved and thus used in this experiment. The two 
compounds were 4-bromomethyl phenyl boronic acid and glucuronic acid (compound 1) and 2-
bromomethyl phenyl boronic acid and acetylneuraminic acid (compound 6). Compound 1 
showed no hemagglutinin characteristics demonstrated by the lack agglutination with all three 
red cell blood types.  
Although compound 6 did not show any agglutination with respect to macroscopic 
observations, compound 6 did show some microscopic observation. While there was no visible 
agglutination with A or O positive cells, compound 6 did show some slight hemagglutination 
with B positive cells. Compound 6 demonstrated some microscopic agglutination with group B 
Rh positive human red cells (figure 3). The agglutination was visible through some small clumps 
throughout the fields. For example, the pointer demonstrates a small visible clump of red blood 
cells after testing the red cells with 2-bromomethyl phenyl boronic acid and acetylneuraminic 
acid. These results suggest some selective hemagglutinin or lectin activity for compound 6.  
The research purpose was to determine and analyze lectin properties in synthetically 
produced compounds. Lectins are used in the lab to help in ABO typing. The research showed 
that 2-bromomethyl phenyl boronic acid and acetylneuraminic acid showed slight agglutination 
with B positive red cells. This may mean that the compound could potentially be used as a lectin 
source in the laboratory for ABO typing.  
This research did have some limitations and strengths. For example, one weakness that I 
had during this research was that I couldn’t test all the compounds because of solubility. Out of 
five compounds that were donated from the chemistry department and Dr. Murray, only two 
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compounds were tested. Further, the two compounds were semi-soluble. Additionally, it took 
awhile to find a good control for the testing. When the tubes were first tested with DMSO and 
red cells, the tubes agglutinated. Thus, a good control had to be sought in order to have validity 
in the actual testing.   
Despite having some limitations in this research, there were also some strengths. For 
example, one strength was that a negative control was derived with a saline and DMSO ratio. 
The control included in this research was .5 ml of DMSO and .25 mL of saline. Additionally, 
another strength in this research was testing the two compounds with the red blood cells. Despite 
having some weaknesses and strengths, there was definitely potential for further research. 
Further research could include testing compound 6 lectin activity on Rh negative red 
cells. This research focused on testing the compounds with A, B, and O positive cells. As a 
result, testing the same compounds with Rh negative red blood cells can indicate whether or not 
the compound is specific for Rh positive, Rh negative, or both. Additionally, because solubility 
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